VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study

Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients

(2010) Lene Meldgaard Knudsen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

(2009) E. Terpos et al.   HAEMATOLOGICA

Staging of Chronic Kidney Disease: Time for a Course Correction

(2008) C. Bauer et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

(2008) J F San-Miguel et al.   LEUKEMIA

Pathogenesis and treatment of renal failure in multiple myeloma

(2008) M A Dimopoulos et al.   LEUKEMIA

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

(2008) Maria Roussou et al.   LEUKEMIA & LYMPHOMA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE